cover
Contact Name
Mohammad Saifur Rohman
Contact Email
hsj@ub.ac.id
Phone
+628973247705
Journal Mail Official
hsj@ub.ac.id
Editorial Address
Department of Cardiology and Vascular Medicine, Dr. Saiful Anwar General Hospital, 3rd Floor CVCU Jl. Jaksa Agung Suprapto No. 2, Malang, Indonesia
Location
Kota malang,
Jawa timur
INDONESIA
Heart Science Journal
Published by Universitas Brawijaya
Core Subject : Health, Science,
HEART SCIENCE is the official open access journal of Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia. The journal publishes articles three times per year in January, May, and September. The journal is a peer reviewed publication and accepts articles for publication from across the world. HEART SCIENCE accepts and publishes articles in the English language only. The primary goal of this journal is to publish clinical and basic research relevant to cardiovascular medicine. The journal covers the following topics: clinical cardiology, interventional cardiology, intensive and acute cardiovascular care, vascular diseases, non-invasive cardiology, pediatric cardiology, cardiac nuclear medicine imaging, arrhythmia, cardiac prevention and rehabilitation, and cardiac surgery. Animal studies are also considered for publication in HEART SCIENCE. To serve the interest of both practicing clinicians and researchers, the journal provides platform or forum for research scholars, intellectuals, and cardiologists to reveal their views and research work for dialogue, education, and interaction to the entire world. HEART SCIENCE publishes original research, reviews, brief reports, case reports, case series, editorial, and commentary. HEART SCIENCE also publishes the special issues and abstracts of papers presented at the annual meeting of the Cardiological Society of Malang.
Articles 383 Documents
A systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in de novo and in-stent restenosis coronary bifurcation lesions Dzikrul Haq Karimullah, Muchammad; Saputra, Pandit Bagus Tri; Alkaff, Firas Farisi; Oktaviono, Yudi Her; Nugraha, Ricardo Adrian; Faizah, Novia Nurul; Widiarti, Wynne; Aufazhafarin, Nadhifa Tanesha; Doman, Zahras Azimuth; Sahara, Rendy Asmaradhana; Niazta, Nisa Amnifolia
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.6

Abstract

Background: Coronary bifurcation lesions are notoriously difficult to treat percutaneously and may require advanced techniques. Drug-eluting balloons (DCBs) have several advantages over drug-eluting stents (DESs), including the ability to maintain arterial physiology, reduce the risk of stent thrombosis, and eliminate the need for permanent metal implants. However, it remains uncertain which treatment will work best. Objective: This study evaluated DCBs and DESs in coronary bifurcation lesions using subgroup analyses based on lesion type and location. Methods: We searched scientific databases for relevant publications up until May 31, 2025. In order to synthesise the results, a random-effects model was employed. To determine the possibility of bias, the ROBINS-I was utilized, and to measure the level of heterogeneity across the studies, the I³ statistic was used. Results were analyzed clinically and angiographically. This subgroup analysis focused on the position of the bifurcation and the kind of lesion (new, internal, or all sites). Result: Eleven research were deemed eligible for inclusion. There was a trend toward fewer major adverse cardiac events (MACE) with DCB compared to DES in the whole cohort, however the trend was not statistically significant (OR0.77, 95% CI0.58-1.02; p=0.07; I²=0%). Both major adverse cardiac events (MACE) and target lesion revascularization (TLR) were significantly reduced in de novo bifurcations when DCB was used (OR0.61, 95% CI 0.41-0.89; p=0.01). Myocardial infarction, target vessel revascularization, in-stent thrombosis, and cardiac mortality were not significantly different among groups. Both the early and late lumen loss and gain seen on angiograms were within the normal range. Conclusion: In de novo bifurcation lesions, DCB demonstrates reduced MACE and TLR versus DES, supporting its role as a stent-free alternative. Randomized controlled trials with greater sample sizes and prolonged follow-up are warranted.
Multiple left ventricular thrombus following coronary artery bypass graft: An uncommonly documented case report Hutomo, Malombassi Dharmawan Hadiwidjojo; Kurnianingsih, Novi; Muttaqin, Chaidar; Widito, Sasmojo
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.19

Abstract

Background: Left Ventricular Thrombus (LVT) formation after Coronary Artery Bypass Grafting (CABG) is infrequent but may result in life-threatening embolic events. The occurrence of LVT following CABG is linked to impaired left ventricular function, regional wall motion abnormalities (RWMAs), hypercoagulability, and an increased inflammatory response subsequent to heart surgery. The interplay of these factors predisposes patients to thrombus development, particularly in those with a history of myocardial infarction, reduced left ventricle ejection fraction (LVEF), pre-existing endothelial injury, or hypercoagulable conditions. Case Presentations: A 65-year-old female with reduced LVEF, 36% by biplane, and RWMAs developed multiple LVT following CABG, as revealed by serial transthoracic echocardiography on postoperative day 6. There was no intracardiac thrombus confirmed preoperatively by transthoracic echocardiography and intraoperatively by transesophageal echocardiography. On follow-up, hypercoagulable risk factors was observed, and adenocarcinoma was diagnosed by bone survey and ultrasound-guided biopsy, suggestive of a metastatic process. A complete resolution of multiple LVTs was achieved after three months of administration of warfarin 2mg daily. Conclusions: This case underscores the importance of echocardiography surveillance among high-risk populations postoperatively. Prompt identification and early initiation of anticoagulants showed to be beneficial in hypercoagulable conditions in carcinoma patient as reported in this case.
Predicting severity and restenosis in coronary artery disease Firman, Doni
Heart Science Journal Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.03.1

Abstract

Despite significant advances in percutaneous coronary intervention (PCI), in-stent restenosis (ISR) remains a major challenge in contemporary coronary intervention. As a complication that is caused by multiple factors, identification of underlying mechanisms is crucial to prevent the event of ISR. A recent data highlights the Tp-e/QTc ratio on a standard ECG as a simple, non-invasive surrogate for SYNTAX score, suggesting a simple, non-invasive marker for coronary lesion complexity. Integrating pre-procedural assessment of coronary disease severity with post-procedural identification of independent risk factors may improve risk stratification and potentially reduce the incidence of ISR. Combined with aggressive secondary prevention strategies, this comprehensive approach may contribute to improved long-term outcomes after PCI.
Effects of metformin and empagliflozin on runt- related transcription factor-2 (RUNX2) mRNA expression in vascular calcification of metabolic syndrome rats Christine, Anastasia; Rohman, Mohammad Saifur; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.5

Abstract

Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype.Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats.Methods:  Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin.Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC.
Diagnostic value of glycated albumin versus HbA1c in predicting coronary artery disease: A systematic review Tiwik Eriskawati; R. A Chatarina Umbul Wahyuni; Joko Prasetyo; Agustin Widyowati
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.4

Abstract

Glycated Albumin (GA) is a medium-term glycemic marker more sensitive to fluctuations in glucose and is unagaffected by factors which affect the lifespan of erythrocytes. Several studies have assessed whether GA has better predictive value or could complement HbA1c for the presence, severity, and prognosis of coronary artery disease (CAD). However, the data remain indefinite. This study compares the efficacy of GA and HbA1c as predictors of the presence, severity, and outcomes of coronary artery disease from recent literature evidence. A systematic review was performed on observational studies, cohort, and cross-sectional studies that reported the association between GA and/or HbA1c with CAD, considering data from PubMed. Studies which evaluated the severity of CAD using angiography/scoring systems like SYNTAX and Gensini, which compared GA and HbA1c, and were related to adults, were included in this review. Various studies reported that GA exhibits a significant association with the severity of coronary stenosis as compared to HbA1c. Furthermore, GA can even observe glycemic fluctuations over a short period, but HbA1c remains valid as a long-term measure. A dual approach may enhance the accuracy in determining cardiovascular risk, particularly in patients with diabetes. In summary, these studies demonstrated that GA outperformed HbA1c in identifying the severity and risk associated with CAD, and when combined, could provide a more robust measure of cardiovascular risk.
Prognostic value of peak high-sensitivity troponin I on in-hospital mortality and length of stay in patients with STEMI and NSTEMI: A retrospective cohort study at tertiary center in East Java Utomo, Yoseph Budi; Anjarwani, Setyasih; Prasetya, Indra
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.13

Abstract

ABSTRACT Background: High-sensitivity cardiac troponin (hs‑Tn) is a cornerstone biomarker in acute myocardial infarction. While its diagnostic role is well established, the prognostic value of peak hs‑Troponin I (hs‑TnI) on in-hospital outcomes remains variable. Objectives: To investigate the effect of peak hs-TnI levels on in-hospital mortality and length of stay among patients with STEMI (ST-segment elevation myocardial infarction) and NSTEMI (non ST-segment elevation myocardial infarction). Methods: This retrospective cohort study used data from the Acute Coronary Syndrome Registry of Dr. Saiful Anwar General Hospital, East Java, Indonesia, collected between July 2023 and December 2024. Adult patients with STEMI or NSTEMI who underwent at least two hs-TnI measurements during early hospitalization were included. Peak hs-TnI was defined as the highest value recorded from early serial measurements without a predefined sampling interval. Multivariable logistic regression analysis was performed to identify independent predictors of in-hospital mortality, and the association with length of hospital stay was evaluated using non-parametric correlation analysis. Results: Among 335 included patients, those who died during hospitalization had significantly higher peak hs-TnI levels than survivors (p < 0.001). After adjustment for age, Killip class, and CRUSADE score, peak hs-TnI remained independently associated with in-hospital mortality. Discriminative performance was modest (AUC 0.63). No significant association was found between peak hs-TnI levels and length of hospital stay Conclusions: Peak hs-TnI from early serial measurements is an independent predictor of in-hospital mortality in STEMI and NSTEMI but is not associated with length of hospital stay.
Misdiagnosed acute coronary syndrome masking a giant mediastinal mass causing obstructive shock: A case report Herbani, Merlita; Satrijo, Budi
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.14

Abstract

Background: Mediastinal tumors with intracardiac extension are exceedingly rare. Nevertheless, when both occur simultaneously, the most severe consequence is obstructive shock from mechanical inflow tract occlusion. This case illustrates the therapeutic paradox between emergency hemodynamic surgical rescue and the perioperative bleeding risk of prior antithrombotic therapy. Case Presentations: We report a 50-year-old man who was initially misdiagnosed with non-ST-elevation acute coronary syndrome (NSTE-ACS) and then received dual antiplatelet therapy (DAPT) and anticoagulant from the previous hospital. He then developed superior vena cava (SVC) syndrome with progressive hypoxemia and obstructive shock, prompting referral to our tertiary hospital. Bedside echocardiography revealed a large mass in the right atrium that originated from the superior vena cava and intermittently occluded the tricuspid valve. A patent foramen ovale (PFO) with right-to-left shunting was also identified. The multidisciplinary Heart Team recommended emergency open heart surgery for tumour evacuation and PFO repair, despite the substantial bleeding risk. Subsequent histopathology revealed thymic lymphoepithelial carcinoma. The patient succumbed to hemorrhagic shock despite aggressive damage-control resuscitation. Conclusions: This case highlights the critical utility of early point-of-care echocardiography in differentiating structural, mechanical causes of obstructive shock from acute coronary syndrome. It further underscores the therapeutic paradox faced by multidisciplinary Heart Teams when mandatory, emergency surgical decompression carries an extreme risk of catastrophic hemorrhage due to recent aggressive antithrombotic therapy.
Staged TEVAR strategy for a high-risk type B penetrating aortic ulcer in a patient with concurrent sub-threshold ascending thoracic aortic aneurysm: A case report Hutomo, Malombassi Dharmawan Hadiwidjojo; Kurnianingsih, Novi
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.15

Abstract

Background: A penetrating aortic ulcer (PAU) carries a high risk of transmural rupture. An acute, high-risk Type B PAU overlapping with a sub-threshold ascending thoracic aortic aneurysm (ATAA) and secondary aortic regurgitation creates a complex clinical dilemma between localized endovascular repair and highly invasive multi-segment surgical replacement, whereas recommendations for strategic prioritization are sparse in multi-segment aortic disease to prevent premature surgical overtreatment. Case Presentations: A 57-year-old woman presented with sudden, tearing chest pain (VAS 9/10), hypertension emergency (195/110 mmHg), and secondary mild aortic regurgitation. CT angiography (CTA) revealed multi-segment pathology: an acute, high-risk Type B PAU without pseudoaneurysm formation or intramural hematoma in Ishimaru zone 3 at upper curvature (depth: 13.6 mm, neck width: 25.1 mm) coexists with a 4.8-cm fusiform ATAA. Despite meeting guideline-directed anti-impulse targets, due to high-risk features, an urgent thoracic endovascular aortic repair (TEVAR) was performed to isolate the PAU, electing surveillance of the sub-threshold ATAA over high-morbidity total aortic reconstruction. Following complete PAU exclusion (no endoleak) and resolution of pulmonary congestion, the patient was discharged on post-procedure day 2. At 30-day follow-up, she remained asymptomatic with a stable 4.8-cm ATAA on CTA. Conclusions: Morphologic high-risk features of a PAU and a sub-threshold ATAA may justify an early endovascular intervention staged sequencing strategy, despite chronic ascending aortopathy being managed conservatively through surveillance.
A potential coronary angiographic burden estimation (CABE) index based on age, fasting blood glucose, and atherogenic index of plasma Zenjaya, Kellyn Trycia; Priscilla, Kezia Rachel; Velisia, Maria Angela; Sukmawati, Sang Ayu Putu Wulan; Aditama, Dedi; Jovie, Benny; Diarsvitri, Wienta
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.11

Abstract

Background: Coronary artery disease remains a major contributor to morbidity and mortality worldwide. Simple and accessible tools for estimating coronary angiographic disease burden may facilitate risk stratification, particularly in settings with limited resources.Objective: To develop and temporally internally validate a practical index for estimating coronary angiographic disease burden using routinely available clinical and metabolic parameters.Methods:  We retrospectively analyzed medical records of 414 patients for model derivation and 166 patients for temporal internal validation, who underwent coronary angiography at Dr. Ramelan Naval Central Hospital between 2024 and 2025. Angiographic burden was classified as mild (Gensini score <11) or moderate-to-severe (≥11). Candidate predictors were  evaluated using logistic regression, and model performance was assessed  using receiver operating characteristic (ROC) analysis.Result: Older age, higher fasting blood glucose (FBG), and atherogenic index of plasma (AIP) were independently associated with greater CAD burden (all p < 0.05), and were incorporated into the Coronary Angiographic Burden Estimation (CABE) Index. The model demonstrated fair discrimination in the derivation cohort (AUC 0.726;60.5% sensitivity and 73.2% specificity at the predefined cutoff) and showed consistent performance in the temporal validation cohort (AUC 0.729). Conclusion: The CABE index is a simple, association-based tool that estimates the likelihood of higher coronary angiographic burden using routinely available clinical and metabolic parameters. . The index demonstrated fair discrimination and consistent temporal validation performance. Further external multicenter validation is required before its broader application in clinical decision-making.
In hospital major adverse cardiovascular events in acute heart failure: prognostic role of echocardiographic pulmonary hypertension probability Yogibuana , Valerinna; Rosyidi, Muhammad Azhar; Aditya , Muhammad Reva
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.12

Abstract

Background :  Pulmonary hypertension secondary to left heart disease (PH-LHD) is predominant type of pulmonary hypertension observed in hospitalized acute heart failure (AHF) patients. Bedside echocardiography for AHF patients offers a pragmatic approach for assessing probability of pulmonary hypertension (PH); however, data correlating the probability of PH as determined by echocardiography to in hospital major adverse cardiovascular events (MACE) throughout hospitalisation remain limited. Methods : This retrospective cohort study was undertaken at a single location, gathered data from the AHF registry at Saiful Anwar General Hospital in Malang, Indonesia, from January 2024 to December 2025. Adult patients admitted for acute heart failure who had transthoracic echocardiography (TTE) within 24 hours of arrival were incorporated into study. The probabilities of pulmonary hypertension, assessed via echocardiography, has been classified as low, moderate, or high in accordance with the 2022 ESC/ERS criteria. The principal outcome was in hospital MACE, characterized as in hospital mortality, cardiac arrest necessitating resuscitation, and/or cardiogenic shock needing medicinal or mechanical hemodynamic intervention. A hierarchical multivariate logistic regression analysis was conducted, controlling for age, sex, body mass index (BMI), Killip, left ventricular ejection fraction (LVEF), utilization of mineralocorticoid receptor antagonists (MRA), and angiotensin receptor-neprilysin inhibitor (ARNI) medication.. Results : A total of 403 patients (median age 61 years; 56.6% male) were enrolled in study, with in-hospital MACE occurring in 124 patients (30.8%). The MACE rate increased in parallel with the increase in PH probability categories: 25.7% (Low), 30.4% (Moderate), and 48.0% (High; p < 0.001). Multivariate analysis demonstrated that elevated PH probability was an independent predictor of in hospital MACE across all three hierarchical models (Model 1: OR 2,91, 95% CI 1,67–5,07; Model 2: OR 2,84, 95% CI 1,63–4,95; Model 3: OR 2,97, 95% CI 1,66–5,32; all p < 0,001), even after full adjustment for LVEF and therapy. Killip class was an independent predictor in all models (OR 1,51–1,77). Therapy use: Beta Blocker (BB) (OR 0,54), MRA (OR 0,43), and ARNI (OR 0,19) each independently reduced the risk of MACE. The resultant model exhibited satisfactory discrimination (AUC 0,73, 95% CI 0,68–0,78) and robust calibration (Hosmer Lemeshow p = 0,41). Conclusions : A high probability of PH assessed using echocardiography can detect high-risk AHF and independently forecast MACE during hospitalization, irrespective of LVEF, clinical severity, and treatment modalities. These findings support the use of echocardiography-based PH probability for early bedside risk determination in hospitalized AHF patient.

Filter by Year

2020 2026


Filter By Issues
All Issue Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi Vol. 7 No. 3 (2026): Predicting Restenosis in Coronary Artery Disease Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure Vol. 7 No. 1 (2026): Accelerating Clinical Breakthroughs: The Journey from Molecular Discovery to Pa Vol. 6 No. 4 (2025): The Pursuit of Precision: Navigating Risks, Refining Diagnosis, and Securing Lo Vol. 6 No. 3 (2025): Advancements in Cardiac Imaging : Unlocking New Perspectives on the Heart Visua Vol. 6 No. 2 (2025): The Complexity in the Management of Heart Rhythm Disorder Vol. 6 No. 1 (2025): Challenges in Managing Acute Heart Failure Vol. 6 No. Suppl_July (2025): Supplement Issue : Indonesian Acute Coronary Syndrome Summit in Conjun Vol. 5 No. 4 (2024): The Current Perspective About Cardiometabolic Disease Vol. 5 No. 3 (2024): The Science and Art of Revascularization in Acute Coronary Syndrome Vol. 5 No. 2 (2024): Challenges in the Management of Congenital Heart and Structural Heart Diseases Vol. 5 No. 1 (2024): Inflammation and Cardiovascular Disease Vol. 4 No. 4 (2023): The Science and Art of Caring for Critically III Patients in Intensive Cardiac Vol. 4 No. 3 (2023): The Essensial Role of the Metabolic Syndrome in the Development of Cardiovascul Vol 4, No 2 (2023): Dealing with the Complexity of the Wide Spectrum of Cardiovascular Disease Vol 4, No 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 4 No. 1 (2023): Optimizing Outcome in Acute Cardiac Care Vol. 3 No. 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improv Vol 3, No 4 (2022): Prevention, Screening dan Rehabilitation : The Back Bone of Quality Care Improve Vol. 3 No. 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 3 (2022): Cardiovascular Disease in Young Adulthood: Who, When, and How to Screen? Vol 3, No 2 (2022): Improving ST-Elevation Myocardial Infraction Patients Prognosis Vol 3, No 1 (2022): Assesment and Outcome of Coronary Artery Disease in the Reperfusion Era Vol 2, No 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease Vol 2, No 3 (2021): The Science and Art of Myocardial Revascularization Vol 2, No 2 (2021): Dealing with Vascular Disease Vol 2, No 1 (2021): How to Diagnose Heart Failure and Deal with The Treatment Complexity Vol 1, No 4 (2020): Acute Coronary Syndrome in Daily Practice : Diagnosis, Complication, and Managem Vol 1, No 3 (2020): Management of Coronary Artery Disease: From Risk Factors to The Better Long-Term Vol 1, No 2 (2020): The Assessment of Diagnostic and Treatment Modality in Heart Failure Vol 1, No 1 (2020): The Importance of Adherence to The Guidelines More Issue